Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cancer patients may need higher antibiotic doses to beat superbugs

NCT ID NCT07703644

Knowledge-focused Sponsor: Sizhou Feng Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study looks at whether the standard dose of the antibiotic ceftazidime-avibactam reaches high enough levels in the blood of people with blood cancers or those who have had a stem cell transplant. These patients are at high risk for severe infections from drug-resistant bacteria. Researchers will measure drug levels and track whether the infection clears and if the bacteria become resistant during treatment. The goal is to find out if the usual dose is adequate for this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ceftazidime-avibactam (CAZ-AVI), an antibiotic combination given intravenously
What this could lead to
If successful, this study could help doctors optimize antibiotic dosing for vulnerable blood cancer patients, potentially improving infection outcomes and slowing the rise of drug-resistant bacteria.
What could go wrong
This is a small, observational study that does not test a new treatment or change how the drug is given. It only measures drug levels and outcomes, so it cannot prove that adjusting doses would improve survival or reduce resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of hospitalized patients with hematological malignancies (such as acute leukemia, lymphoma, multiple myeloma, or myelodysplastic syndrome) or those who have underwent/are undergoing autologous or allogeneic hematopoietic stem cell transplantation (HSCT) at the Institute of Hematology \& Blood Diseases Hospital, Chinese Academy of Medical Sciences, who are prescribed standard-dose ceftazidime-avibactam for suspected or confirmed Gram-negative bacterial infections based on routine clinical decisions.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 16 years or older. * Diagnosed with hematological malignancies (including but not limited to acute leukemia, lymphoma, multiple myeloma, or myelodysplastic syndrome \[MDS\]) or having received/undergoing autologous or allogeneic hematopoietic stem cell transplantation (HSCT). * Prescribed ceftazidime-avibactam (CAZ-AVI) therapy for suspected or confirmed Gram-negative bacterial infections based solely on routine clinical decisions. * Expected duration of CAZ-AVI therapy is no less than 72 hours. * Willing and able to comply with the study-specified therapeutic drug monitoring (TDM) and microbiological surveillance. Exclusion Criteria: * Known severe allergy or hypersensitivity to ceftazidime, avibactam, cephalosporins, or other beta-lactam antibiotics. * Confirmed infection caused by metallo-beta-lactamase (MBL)-producing pathogens, without receiving appropriate combination therapy. * Expected survival time of less than 72 hours. * Inability to complete critical pharmacokinetic (TDM) or microbiological sampling. * Pregnancy or lactation. * Any other condition that, in the opinion of the investigator, makes the patient unsuitable for study inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug resistance, bacterial are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gram-negative bacterial infections hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Klebsiella pneumonia Pseudomonas aeruginosa infectious disease Pseudomonas infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug resistance, bacterial Gram-negative bacterial infections Hematologic neoplasms Klebsiella pneumoniae infections Pseudomonas aeruginosa infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.